A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
Trial Parameters
Brief Summary
Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
Eligibility Criteria
Inclusion Criteria: Age ≥18 and ≤70 years old, regardless of gender; Patients with head and neck squamous carcinoma who are pathologically confirmed and fulfill the following conditions: Patients with locally advanced head and neck squamous carcinoma (excluding nasopharyngeal, salivary gland and thyroid malignant tumors) who are initially diagnosed and have no distant metastasis; Non oropharyngeal HNSCC carcinoma and HPV-negative oropharyngeal carcinoma, stages III, IVA and IVB; HPV-positive oropharyngeal cancers, stages II and III; HPV status of oropharyngeal cancer will be determined by p16 immunohistochemistry. Treatable by surgical resection as evaluated by head and neck surgery; Definite lymph node metastasis and lymph node stage is not N0 or Nx. An Eastern Cooperative Oncology Group (ECOG) physical status score of 0 to 1; Have adequate organ and bone marrow function as defined below: Subjects voluntarily enrolled in the study, signed an informed consent form, and were able to com